Logotype for Cereno Scientific

Cereno Scientific (CRNO) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Cereno Scientific

Q3 2026 earnings summary

4 Nov, 2026

Executive summary

  • Three differentiated programs advanced: CS1 in Phase IIb for PAH, CS014 preparing for Phase IIb in PH-ILD, and preclinical CS585 targeting rare thrombotic diseases.

  • Positive CS014 PK bridging results supported a proposed direct path toward Phase IIb, subject to FDA review; EPIMODE site activation and patient recruitment readiness continued.

Financial highlights

  • Q3 2026 operating loss was SEK 17.9m versus SEK 13.5m in Q3 2025; loss after financial items was SEK 27.4m versus SEK 21.3m.

  • 9M 2026 operating loss was SEK 58.8m versus SEK 47.4m; loss after financial items was SEK 86.5m versus SEK 73.0m.

  • Cash and cash equivalents were SEK 40.2m at September 30, 2026, versus SEK 74.2m a year earlier; equity ratio was 47.6% versus 49.5%.

Outlook and guidance

  • EPIMODE targets up to 15 activated sites by end-2026 and more than half of planned sites by end-Q1 2027; recruitment completion is targeted during 2027 and topline results in Q4 2028, subject to recruitment timelines.

  • CS014 IND submission is planned for Q4 2026 and Phase IIb initiation for Q3 2027, subject to regulatory approval and completion of preparations.

  • Additional capital will be needed to execute development plans at the intended pace; financing and partnership options remain under evaluation.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Cereno Scientific